General Counsel James R. Kasinger sells 11,542 shares for $619,492.35 at CRSP; holds 74,880 shares post-sale.
James R. Kasinger, General Counsel and Secretary, executed 2 separate sales totaling 11,542 shares for $619,492.35 at blended average price $53.67 on 2025-02-18 and 2025-02-19. This represents a 13.4% reduction of his pre-transaction holdings. The sales occur in a company context marked by significant operational challenges: CRISPR reported quarterly revenue of $602,000.00, full-year net income of negative $85,942,000.00, and annual revenue decline of 90.0%. The 30-day price appreciation of 30.8% provides context for the sale timing relative to recent market performance, though the stock remains 40.5% below its 52-week high of $89.12. For a general counsel, a partial holding reduction warrants investor attention given the senior role's access to material information and typical low expected turnover among C-suite officers with governance responsibility.